Study at urban cancer center finds 75 percent of its depressed patients were previously undiagnosed

SAN DIEGO, Sept. 24, 2017 /PRNewswire-USNewswire/ -- A new study of patients at an urban cancer center points to a potentially serious problem that may limit the impact of clinical cancer care—undiagnosed depression. Among the 40 percent of patients at the center who were diagnosed with depression, three in four had not previously been told they were depressed. Female patients and disabled patients also were more likely to be depressed, according to research presented today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

A web of physiological, psychological and socioeconomic factors associated with having and being treated for cancer—such as severe physical pain, side effects of medication, financial concerns, fears and anxieties about mortality and changes in lifestyle and life plans—place cancer patients at a higher risk of developing depression. The National Cancer Institute (NCI) estimates that 15 to 25 percent of the general cancer patient population has depression—a rate two to three times that of the general population. Approximately seven percent of U.S. adults experience major depression, according to the National Institutes for Mental Health (NIMH).

"Depression prevalence continues to be high among cancer patients, especially those receiving treatment at an urban cancer center, as well as those who identify as female or are disabled by their disease. Alarmingly, most of these patients remain undiagnosed and untreated, indicating an important gap in cancer care and an opportunity to improve patient outcomes," said Jason Domogauer, PhD, lead author of the study and an MD/PhD candidate at Rutgers University New Jersey Medical School in Newark, New Jersey.

Findings in this study are based on an examination of 400 cancer patients who received treatment at the University Hospital Cancer Center in Newark, New Jersey, between 2013 and 2016. Researchers assessed depression using a minimum score of 16 on the Center for Epidemiologic Studies Depression Scale.

The average patient age was 55 years (range 20-86 years), and 53 percent of patients were female. The racial/ethnic breakdown of patients was 48 percent African-American, 29 percent non-Hispanic white and 16 percent Hispanic. Nearly equal numbers of patients reported being able to work (including those working full-time, part-time and unemployed) (49%) or being unable to work due to disability (51%). Most patients (85%) received radiation therapy as part of their cancer treatment.

Depression was diagnosed in 40 percent of the patients at this urban cancer center, which is roughly twice as large as the NCI estimate of 15 to 25 percent for the general cancer patient population. Moreover, depression was previously undiagnosed in three-fourths of these cases, meaning that roughly 30 percent of the patients at this cancer center suffered from undiagnosed and untreated depression.

Depression was more common among female patients (47%) than among male patients (32%) (odds ratio [OR] 1.9, p = 0.007) and among patients who were unable to work due to disability (48% vs. 33% of those able to work; OR 1.9, p = 0.005). NIMH statistics for the general U.S. adult population also point to a higher risk of depression for women and people with a disability, particularly among older adults. Depression prevalence did not differ significantly among racial/ethnic groups. Logistic regression was used to compare depression prevalence among the patient groups.

Looking specifically at patients who were previously not diagnosed with depression, the effects of being female or unable to work persisted. Among this subgroup, depression was more common among women (43% vs. 29% male; OR 1.9, p = 0.02) and disabled patients (43% vs. 31% able to work; OR 1.9, p = 0.03).

"Depression is widely recognized as an underdiagnosed disorder, particularly among older adults and cancer patients. Our findings point to a clear need for action including depression screening during initial and continuing patient visits, initiation of mental health treatments for identified patients and increased collaboration with mental health providers in cancer treatment centers. These efforts are particularly important for patients in urban centers, those who are female and those who are unable to work because of their disease," said Dr. Domogauer.

The abstract, "Study of total and undiagnosed depression in a cancer patient population at an urban cancer center," will be presented in detail during a news briefing and an oral abstract session at ASTRO's 59th Annual Meeting in San Diego (full details below). To schedule an interview with Dr. Domogauer and/or outside experts, contact ASTRO's media relations team on-site at the San Diego Convention Center, September 24 through 27, by phone at 703-286-1600 or by email at [email protected].

ATTRIBUTION TO THE AMERICAN SOCIETY OF RADIATION ONCOLOGY (ASTRO) ANNUAL MEETING REQUESTED IN ALL COVERAGE.

This news release contains additional and/or updated information from the study author(s). Full original abstract and author disclosures available from [email protected] or at www.astro.org/annualmeeting.

Study Presentation Details

• Scientific Session: Sunday, September 24, 1:15 – 2:45 p.m. Pacific time, San Diego Convention Center, room 7A/B
• News Briefing: Tuesday, September 26, 1:00 – 2:00 p.m. Pacific time, San Diego Convention Center, room 24C, webcast: http://www.bit.do/astro17-3

Resources on Cancer and Radiation Therapy

• Video: An Introduction to Radiation Therapy (Spanish version)
• Additional brochures, videos and information on radiation therapy from RTAnswers.org
• ASTRO's clinical practice statements and guidelines

ABOUT ASTRO'S ANNUAL MEETING
ASTRO's 59th Annual Meeting, the world's largest scientific meeting in radiation oncology, will be held September 24-27, 2017, at the San Diego Convention Center. The 2017 Annual Meeting is expected to attract more than 11,000 attendees from across the globe, including oncologists from all disciplines and members of the entire radiation oncology team. More than 2,800 abstracts sharing results from clinical trials and other research studies will be presented in conjunction with educational sessions and keynote addresses that underscore the meeting's theme, "The Healing Art and Science of Radiation Oncology." Led by ASTRO President Brian Kavanagh, MD, MPH, FASTRO, the 2017 meeting will feature keynote addresses from Richard D. Zane, MD, FAAEM, Chief Innovation Officer for the University of Colorado Health System; Lucy Kalanithi, MD, FACP, widow of Paul Kalanithi, MD, the best-selling author of "When Breath Becomes Air," with Heather Wakelee, MD, Paul's oncologist; and Vinay K. Prasad, MD, MPH, an assistant professor of medicine at the Oregon Health & Science University. During the four-day meeting, more than 200 exhibitors will demonstrate cutting-edge technology and medical device innovations for radiation oncology. Visit us online for more information about ASTRO's 59th Annual Meeting or press opportunities at the meeting.

ABOUT ASTRO
The American Society for Radiation Oncology (ASTRO) is the world's largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org and follow us on our blog, Facebook and Twitter.

Contact: Liz Gardner
703-286-1600
[email protected]

Leah Kerkman Fogarty
703-839-7336
[email protected]

SOURCE American Society for Radiation Oncology

Related Links

http://www.astro.org